AbbVie Inc (NYSE:ABBV) Shares Bought by Private Wealth Partners LLC
Private Wealth Partners LLC boosted its stake in shares of AbbVie Inc (NYSE:ABBV) by 10.5% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 5,250 shares of the company’s stock after acquiring an additional 500 shares during the period. Private Wealth Partners LLC’s holdings in AbbVie were worth $382,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Bank Hapoalim BM raised its position in shares of AbbVie by 20.2% in the second quarter. Bank Hapoalim BM now owns 18,540 shares of the company’s stock valued at $1,348,000 after buying an additional 3,110 shares during the last quarter. H D Vest Advisory Services grew its holdings in shares of AbbVie by 14.5% in the second quarter. H D Vest Advisory Services now owns 26,852 shares of the company’s stock valued at $1,953,000 after purchasing an additional 3,402 shares during the period. Achmea Investment Management B.V. grew its holdings in shares of AbbVie by 1.5% in the second quarter. Achmea Investment Management B.V. now owns 166,548 shares of the company’s stock valued at $12,114,000 after purchasing an additional 2,413 shares during the period. Colrain Capital LLC grew its holdings in shares of AbbVie by 347.6% in the second quarter. Colrain Capital LLC now owns 21,260 shares of the company’s stock valued at $1,546,000 after purchasing an additional 16,510 shares during the period. Finally, Enlightenment Research LLC purchased a new stake in shares of AbbVie in the second quarter valued at about $675,000. Institutional investors own 70.03% of the company’s stock.
ABBV stock traded down $0.02 during mid-day trading on Thursday, hitting $67.52. 2,969,551 shares of the company were exchanged, compared to its average volume of 9,901,970. The firm has a market capitalization of $98.41 billion, a P/E ratio of 8.54, a PEG ratio of 1.58 and a beta of 0.96. The business has a fifty day simple moving average of $67.82 and a 200-day simple moving average of $76.22. AbbVie Inc has a 12-month low of $62.66 and a 12-month high of $98.70.
The business also recently announced a quarterly dividend, which was paid on Thursday, August 15th. Shareholders of record on Monday, July 15th were paid a dividend of $1.07 per share. This represents a $4.28 annualized dividend and a yield of 6.34%. The ex-dividend date of this dividend was Friday, July 12th. AbbVie’s dividend payout ratio (DPR) is presently 54.11%.
In related news, Director Roxanne S. Austin bought 11,500 shares of the stock in a transaction on Wednesday, June 26th. The stock was bought at an average price of $67.50 per share, with a total value of $776,250.00. Following the completion of the purchase, the director now directly owns 52,114 shares in the company, valued at approximately $3,517,695. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jeffrey Ryan Stewart acquired 15,552 shares of the stock in a transaction dated Friday, August 16th. The stock was acquired at an average cost of $64.44 per share, with a total value of $1,002,170.88. Following the purchase, the senior vice president now owns 65,304 shares of the company’s stock, valued at approximately $4,208,189.76. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 152,452 shares of company stock valued at $10,128,541. 0.08% of the stock is currently owned by insiders.
A number of brokerages recently issued reports on ABBV. Piper Jaffray Companies raised shares of AbbVie from a “neutral” rating to an “overweight” rating and set a $80.00 price objective for the company in a report on Tuesday. Leerink Swann raised shares of AbbVie to a “buy” rating in a report on Tuesday, July 2nd. Goldman Sachs Group began coverage on shares of AbbVie in a report on Tuesday, May 28th. They issued a “neutral” rating and a $84.00 price objective for the company. BMO Capital Markets raised shares of AbbVie from an “underperform” rating to a “market perform” rating and upped their price objective for the company from $71.00 to $79.00 in a report on Sunday, April 28th. Finally, Credit Suisse Group set a $78.00 price objective on shares of AbbVie and gave the company a “sell” rating in a report on Friday, April 26th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $92.05.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Featured Article: What is the Quick Ratio?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.